Should I invest in Phio Pharmaceuticals in short term?
 | By Raphi Shpitalnik | Macroaxis Story |
In today's thesis, we are going to go over some ideas for Phio Pharmaceuticals investors who consider a position in the company. We will inspect the possibilities of making Phio Pharmaceuticals into a steady grower in August. Phio Pharmaceuticals Corp is at this time traded for 2.60. The entity has historical hype elasticity of -0.06. The average price elasticity to hype of competition is about 0.17. The firm is projected to decline in value after the next press release with price expected to drop to 2.54. The average volatility of headline impact on the company stock price is about 7230.0%. The price decrease on the next news is expected to be -2.31% whereas the daily expected return is at this time at 0.61 percent. . Given the investment horizon of 30 days, the next projected announcement will be in about 3 days. This firm moves indifferently to market moves.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
The company's average rating is Strong Buy from 1 analysts. We provide buy or sell recommendations to complement the recent expert consensus on Phio Pharmaceuticals Corp. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. In general, we focus on analyzing Phio Pharmaceuticals (PHIO) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Phio Pharmaceuticals Corp daily price indicators and compare them against related drivers.
The successful prediction of Phio Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Phio Pharmaceuticals Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Phio Pharmaceuticals based on Phio Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Phio Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Phio Pharmaceuticals's related companies.
Watch out for price decline
Please consider monitoring Phio Pharmaceuticals on a daily basis if you are holding a position in it. Phio Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Phio Pharmaceuticals stock to be traded above the $1 level to remain listed. If Phio Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Phio expected Price
Phio Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Phio Pharmaceuticals Gross Profit
Phio Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Phio Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Phio Pharmaceuticals Gross Profit growth over the last 10 years. Please check Phio Pharmaceuticals' gross profit and other fundamental indicators for more details.
Breaking down the case for Phio Pharmaceuticals
Phio Pharmaceuticals preserves 7.02 x of current ratio. Phio Pharmaceuticals currently falls under 'Micro-Cap' category with current market capitalization of 10.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Phio Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Phio Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Net Loss for the year was (9.14 M) with loss before overhead, payroll, taxes, and interest of (4.28 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Phio Pharmaceuticals Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.